newsfeed-en
@SachsAssociates
17. Feb 2023 via Twitter
Mr. Fazeli brings with him over 25 years of experience conducting equity research as a pharmaceutical analyst.Meet Sam at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing @SamFazeli8 pic.twitter.com/ylC3Rtf1RL— Sachs Associates (@SachsAssociates) February 17, 2023
@SachsAssociates
15. Feb 2023 via Twitter
Meet Adrian Dawkes, Managing Director of @PharmaVentures @ #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine #venturecapital pic.twitter.com/9rw3RBz8Vm— Sachs Associates (@SachsAssociates) February …
@SachsAssociates
13. Feb 2023 via Twitter
Meet @pdc_line at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine #venturecapital #hybrid #hybridevent #venturecapital pic.twitter.com/vVUk77TYl8— Sachs Associates (@SachsAssociates) February 13, …
@SachsAssociates
9. Feb 2023 via Twitter
invIOs stands for innovative immuno-oncology and is a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies. Meet invIOs at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW pic.twitter.com/cisCUTRCmS— Sachs Associates (@SachsAssociates) February 9…
@SachsAssociates
8. Feb 2023 via Twitter
Deep Breath Intelligence(@the_dbi) is a MedTech company unleashing the huge potential of analyzing exhaled breath by applying machine learning algorithms.Meet Deep Breath Intelligence at #Sachs_EHTFMore info @ https://t.co/FwbW1GHhde#Sachs_EHTF #Sachs_SSLSW #partnering pic.twitter.com/cutbJbFIVr— Sachs Associates (@SachsAssociates) February 8…
@SachsAssociates
8. Feb 2023 via Twitter
BiPER Therapeutics is a biotechnology company developing first-in-class small molecules to treat cancers. Meet BiPER Therapeutics at #Sachs_ELSFMore info @ https://t.co/hgPC4hxz57#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health pic.twitter.com/hkg4PbAYUI— Sachs Associates (@SachsAssociates) February 8, 2023
@SachsAssociates
7. Feb 2023 via Twitter
Dr. Yves Nordmann, M.D., is co-founder & Chief Medical Officer (CMO) of https://t.co/g4Yox7JWrN Ltd. Meet Yves at #Sachs_EHTFMore info @ https://t.co/FwbW1GHhde#Sachs_EHTF #Sachs_SSLSW #partnering #businessdevelopment #bd #licensing #health #investment #healthcare pic.twitter.com/d7XNhXnuoY— Sachs Associates (@SachsAssociates) February 7…
@SachsAssociates
1. Feb 2023 via Twitter
Meet IAMA Therapeutics at #Sachs_ELSFMore info @ https://t.co/hgPC4hy6UF#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine #venturecapital #hybrid #hybridevent #venturecapital pic.twitter.com/fFJ8LNNPbC— Sachs Associates (@SachsAssociates) Febru…
@SachsAssociates
1. Feb 2023 via Twitter
Atriva is a mid-stage clinical development company with first-in-class host-targeting therapies to treat severe viral infections when prevention failed.Meet Atriva at #Sachs_ELSFMore info @ https://t.co/hgPC4hy6UF#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing pic.twitter.com/xRVghanPdv— Sachs Associates (@SachsAssociates) Februa…
@SachsAssociates
1. Feb 2023 via Twitter
Meet Relief Therapeutics at #Sachs_ELSFMore info @ https://t.co/hgPC4hy6UF#Sachs_ELSF #SSLSW #lifesciences #partnering #bd #licensing #health #investment #startup #healthcare #innovation #biotech #business #invest #medicine #venturecapital #hybrid #hybridevent #venturecapital pic.twitter.com/XHsXNT8sRp— Sachs Associates (@SachsAssociates) Feb…